Patient Palatability and Preference of 3 Potassium Binders in Patients with Chronic Kidney Disease and Hyperkalaemia

Trial Identifier: D9480C00016
Sponsor: AstraZeneca
Labcorp Drug Development Inc.
NCTID:: NCT04566653
Start Date: October 2020
Primary Completion Date: January 2022
Study Completion Date: January 2022

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Canada, ON Toronto, ON, Canada, M5G 2C4
Canada, QC Greenfield Park, QC, Canada, J4V 2H1
Canada, QC Quebec, QC, Canada, G1L 3L5
Canada, Quebec Montreal, Quebec, Canada, H1T 2M4
France Amiens, France, 80054
France Nantes, France, 44093
France Nice, France, 06000
Germany Muenchen, Germany, 80804
Germany Tuebingen, Germany, 72076
Germany Villingen-Schwenningen, Germany, 78052
Italy Bari, Italy, 70124
Italy Genova, Italy, 16132
Italy Parma, Italy
Italy Pavia, Italy, 27100
Italy Piacenza, Italy, 29121
Italy Torino, Italy, 10141
Spain Barcelona, Spain, 8035
Spain Cordoba, Spain, 14004
Spain Córdoba, Spain, 14004
Spain La Coruña, Spain, 15006
Spain Lleida, Spain, 25198
Spain Madrid, Spain, 28031
Sweden Eskilstuna, Sweden, 631 88
Sweden Malmö, Sweden, 214 28
Sweden Stockholm, Sweden, 182 88
United States of America, FL Temple Terrace, FL, United States of America, 33637
United States of America, FL West Palm Beach, FL, United States of America, 33411